Trial Profile

A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 13 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ansuvimab (Primary) ; Atoltivimab/maftivimab/odesivimab (Primary) ; Remdesivir (Primary) ; Antivirals; Porgaviximab
Indications Ebola virus infections
Focus Registrational; Therapeutic Use
Acronyms PALM

Most Recent Events

22 Dec 2020 According to the Food and Drug Administration media release, the US FDA has approved EbangaT for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection).
21 Dec 2020 Results presented in a Food and Drug Administration media release.
03 Dec 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com